AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12617376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis medicinal extracts (CME)
Number of subjects: 24
Study 12617376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12617376 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-containing CME
Number of subjects: 24
Study 10952113 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-level preview method
Number of subjects: 240
Study 10952113 — intervention group
Group type: COMPARATOR
Intervention: Traditional preview method
Number of subjects: 240
Study 9080890 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure illustrating typical changes of melanoma
Number of subjects: 93
Study 9080890 — intervention group
Group type: COMPARATOR
Intervention: No educational brochure (control group)
Number of subjects: 93
Study 9080890 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 93
Study 8442620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours)
Number of subjects: 257
Study 3620399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 60
Study 3620399 — intervention group
Group type: COMPARATOR
Intervention: No oxytocin infusion (control)
Number of subjects: 60
Study 31909811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) - 20 g daily during pregnancy and 6 months postpartum; infants received LNS from 6 to 18 months.
Number of subjects: 869
Study 31909811 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) - 1 capsule daily during pregnancy and 6 months postpartum; combined with IFA group for analysis.
Number of subjects: 869
Study 31909811 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) - 1 capsule daily during pregnancy, then placebo postpartum; combined with MMN group for analysis.
Number of subjects: 869
Study 30430209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal PaCO2 (4.5-4.7 kPa)
Number of subjects: 123
Study 30430209 — intervention group
Group type: COMPARATOR
Intervention: High-normal PaCO2 (5.8-6.0 kPa)
Number of subjects: 123
Study 30430209 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (PaO2 10-15 kPa)
Number of subjects: 123
Study 30430209 — intervention group
Group type: COMPARATOR
Intervention: Moderate hyperoxia (PaO2 20-25 kPa)
Number of subjects: 123
Study 30430209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal PaCO2
Number of subjects: 123
Study 30430209 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperoxia
Number of subjects: 123
Study 30430209 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 123
Study 26940848 — intervention group
Group type: EXPERIMENTAL
Intervention: User comments addressing tentativeness
Number of subjects: 70
Study 26940848 — intervention group
Group type: COMPARATOR
Intervention: User comments not addressing tentativeness
Number of subjects: 70
Study 26940848 — intervention group
Group type: COMPARATOR
Intervention: No user comments
Number of subjects: 70
Study 25223267 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV0+BCG
Number of subjects: 430
Study 25223267 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 430
Study 21831580 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus (SV) approach
Number of subjects: 90
Study 21831580 — intervention group
Group type: COMPARATOR
Intervention: Medial Parapatellar (MP) approach
Number of subjects: 90
Study 19110245 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga practice and guided yogic relaxation
Number of subjects: 122
Study 19110245 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal exercises
Number of subjects: 122
Study 17642233 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 0
Study 17642233 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 0
Study 15987403 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal formula fermented with Lactobacillus plantarum 299v (Lp 299v)
Number of subjects: 17
Study 15987403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study 12363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced antimicrobial usage (from 1.5 to 1.1 courses/year)
Number of subjects: 743
Study 12363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antimicrobial use among children <7 years old (from 13.6 to 11.1 defined daily dosages/1000 children per day)
Number of subjects: 743
Study 12363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide interventions to reduce antimicrobial usage
Number of subjects: 743
Study 9609785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet (HiCHO)
Number of subjects: 10
Study 9609785 — intervention group
Group type: COMPARATOR
Intervention: Low-CHO diet (LoCHO)
Number of subjects: 10
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed nine hole peg test
Number of subjects: 50
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 meter walk test
Number of subjects: 50
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams delayed recall test
Number of subjects: 50
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Aphasia Severity Rating Scale
Number of subjects: 50
Study 7815103 — intervention group
Group type: COMPARATOR
Intervention: Barthel Disability Index (BDI)
Number of subjects: 50
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 50
Study 7815103 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of abnormal fast tests
Number of subjects: 50
Study 1704561 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-tipped leads
Number of subjects: 18
Study 1704561 — intervention group
Group type: COMPARATOR
Intervention: Porous platinum leads
Number of subjects: 18
Study 70320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape-slide program
Number of subjects: 180
Study 70320 — intervention group
Group type: COMPARATOR
Intervention: Tape-slide program alone
Number of subjects: 180
Study 31937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Directed Activity Program (PDAP)
Number of subjects: 73
Study 31937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Directed Activity Program (PDAP) at three months post discharge
Number of subjects: 73
Study 31164185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists
Number of subjects: 101
Study 31164185 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 101
Study 28488553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vascular care in GP practices
Number of subjects: 116
Study 28488553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 26506205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration bladder (BG)
Number of subjects: 0
Study 26506205 — intervention group
Group type: COMPARATOR
Intervention: Traditional canteen (CG)
Number of subjects: 0
Study 24383602 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 89
Study 24383602 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus 1 μg·kg(‐1) dexmedetomidine
Number of subjects: 89
Study 24383602 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus 2 μg·kg(‐1) dexmedetomidine
Number of subjects: 89
Study 21672910 — intervention group
Group type: EXPERIMENTAL
Intervention: CHICA system intervention (tailored prompt for TB and iron-deficiency anemia)
Number of subjects: 2239
Study 21672910 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic prompt, no screening)
Number of subjects: 2239
Study 19309747 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil once daily for 4 weeks (Phase 1)
Number of subjects: 82
Study 19309747 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued modafinil for an additional 4 weeks (Phase 2)
Number of subjects: 82
Study 19309747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Phase 2)
Number of subjects: 82
Study 16750463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 4 mg SC
Number of subjects: 577
Study 16750463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 15729231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation (MPEC)
Number of subjects: 52
Study 15729231 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 52
Study 12860797 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 31
Study 10206720 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh, 0.55 M)
Number of subjects: 14
Study 10206720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP, 1.5x 10(‐5) M)
Number of subjects: 14
Study 10206720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACh and VIP
Number of subjects: 14
Study 10206720 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (H1-antagonist) pretreatment before ACh injection
Number of subjects: 14
Study 7486088 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.1% ropivacaine
Number of subjects: 40
Study 7486088 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.2% ropivacaine
Number of subjects: 40
Study 7486088 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.3% ropivacaine
Number of subjects: 40
Study 7486088 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 40
Study 2360502 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg once daily)
Number of subjects: 39
Study 2360502 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 to 800 mg once daily)
Number of subjects: 39
Study 7026343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 532
Study 7026343 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 532
Study 29672306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (Arm A)
Number of subjects: 147
Study 29672306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) (Arm B)
Number of subjects: 147
Study 29672306 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback (Arm C)
Number of subjects: 147
Study 28718910 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing subsidies plus housing case management
Number of subjects: 75
Study 28718910 — intervention group
Group type: COMPARATOR
Intervention: Housing case management alone
Number of subjects: 75
Study 26044228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and water capsule-guided local injection of botulinum toxin type A (group B)
Number of subjects: 157
Study 26044228 — intervention group
Group type: COMPARATOR
Intervention: Oral drug treatment (group A)
Number of subjects: 157
Study 23108953 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 (10 mg/kg QW) plus cisplatin/capecitabine (CX)
Number of subjects: 171
Study 23108953 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 (3 mg/kg QW) plus cisplatin/capecitabine (CX)
Number of subjects: 171
Study 23108953 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin/capecitabine (CX)
Number of subjects: 171
Study 22030577 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 18
Study 22030577 — intervention group
Group type: COMPARATOR
Intervention: Control (Hand-off sham intervention)
Number of subjects: 18
Study 18672290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (2 mg twice daily)
Number of subjects: 33
Study 18672290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17039647 — intervention group
Group type: EXPERIMENTAL
Intervention: Orapred
Number of subjects: 31
Study 17039647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediapred
Number of subjects: 31
Study 17039647 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone suspension
Number of subjects: 31
Study 17039647 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone suspension
Number of subjects: 31
Study 17039647 — intervention group
Group type: EXPERIMENTAL
Intervention: cherry‐flavored prednisolone suspensions
Number of subjects: 31
Study 12694213 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of TNFA-308*1/2 (*G/A) genotype
Number of subjects: 86
Study 12694213 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of TNFA-308*2/2 (*A/A) genotype
Number of subjects: 86
Study 12694213 — intervention group
Group type: COMPARATOR
Intervention: TNFA-308 genotypes distribution
Number of subjects: 86
Study 11885186 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-loading method
Number of subjects: 829
Study 11885186 — intervention group
Group type: COMPARATOR
Intervention: All failures counted
Number of subjects: 829
Study 9005589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C 30 mg for 12 months
Number of subjects: 60
Study 9005589 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C 40 mg for 6 months
Number of subjects: 60
Study 1471536 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 151
Study 1471536 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 151
Study 6376827 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Number of subjects: 0
Study 6376827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoglucid (Epodyl)
Number of subjects: 0
Study 6376827 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 0
Study 29787483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 30
Study 29787483 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS at 40% of maximal stimulator output
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS at 70% of maximal stimulator output
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse PNS
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired (100-Hz)-pulse PNS
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse EMS
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of TMS at 70% of maximal stimulator output
Number of subjects: 19
Study 27297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of paired-pulse PNS
Number of subjects: 19
Study 27297772 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control condition)
Number of subjects: 19
Study 25540035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy
Number of subjects: 170
Study 25540035 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 170
Study 23316598 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group receiving preventive measures designed for each risk category applied periodically.
Number of subjects: 0
Study 23316598 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standardized preventive measures at regular intervals.
Number of subjects: 0
Study 19895780 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/d
Number of subjects: 70
Study 18794543 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Estramustine (D/E); 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks, plus prednisone (10 mg/d)
Number of subjects: 150
Study 18794543 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (D); 35 mg/m(2) on days 2 and 9, every 3 weeks, plus prednisone (10 mg/d)
Number of subjects: 150
Study 15887946 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences conducted via teleconference
Number of subjects: 56
Study 15887946 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 56
Study 12766861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg daily)
Number of subjects: 1987
Study 12766861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1987
Study 12372154 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron pots
Number of subjects: 113
Study 12372154 — intervention group
Group type: COMPARATOR
Intervention: Aluminium pots
Number of subjects: 113
Study 10329815 — intervention group
Group type: COMPARATOR
Intervention: Inhaled albuterol 400 micrograms (low dose) after placebo
Number of subjects: 16
Study 10329815 — intervention group
Group type: COMPARATOR
Intervention: Inhaled albuterol 1600 micrograms (high dose) after placebo
Number of subjects: 16
Study 10329815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 400 micrograms (low dose) after formoterol 12 micrograms
Number of subjects: 16
Study 10329815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 1600 micrograms (high dose) after formoterol 12 micrograms
Number of subjects: 16
Study 10329815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 400 micrograms (low dose) after salmeterol 50 micrograms
Number of subjects: 16
Study 10329815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 1600 micrograms (high dose) after salmeterol 50 micrograms
Number of subjects: 16
Study 10329815 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of beta2-adrenoceptor polymorphisms
Number of subjects: 16
Study 7757335 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin therapy for 12 months
Number of subjects: 0
Study 7757335 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 2185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/d
Number of subjects: 0
Study 2185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/d
Number of subjects: 0
Study 2185303 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/d
Number of subjects: 0
Study 2185303 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran 50 mg/d
Number of subjects: 0
Study 7033745 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pharmacological treatment
Number of subjects: 582
Study 7033745 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 582
Study 31805992 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin levels at DMARD tapering/stopping
Number of subjects: 161
Study 31805992 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin predictive value for flare
Number of subjects: 161
Study 27323323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral walking training
Number of subjects: 51
Study 27323323 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking training
Number of subjects: 51
Study 27323323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 26372274 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily rosuvastatin
Number of subjects: 74
Study 26372274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23401474 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (160 mg)
Number of subjects: 16
Study 23401474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21617837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes of resistance training per day for 10 weeks
Number of subjects: 198
Study 21617837 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 minutes of resistance training per day for 10 weeks
Number of subjects: 198
Study 21617837 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly health information)
Number of subjects: 198
Study 20396722 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon in combination with SCENAR therapy
Number of subjects: 0
Study 20396722 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in combination with SCENAR therapy
Number of subjects: 0
Study 17519319 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml water
Number of subjects: 16
Study 17519319 — intervention group
Group type: COMPARATOR
Intervention: isoosmotic saline
Number of subjects: 16
Study 17519319 — intervention group
Group type: COMPARATOR
Intervention: 50 ml water
Number of subjects: 16
Study 15531229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant
Number of subjects: 125
Study 15531229 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue application)
Number of subjects: 125
Study 11442893 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 182
Study 11442893 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 182
Study 9761082 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy involving cardiac catheterization within 4 to 48 hours and revascularization with angioplasty or bypass surgery if feasible
Number of subjects: 0
Study 9761082 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy, where patients are referred for catheterization only for recurrent pain at rest or provokable ischemia
Number of subjects: 0
Study 7822629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg
Number of subjects: 12
Study 7822629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (E) loading dose of 500 micrograms/kg/min for 1 min
Number of subjects: 40
Study 2900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (E) loading dose of 500 micrograms/kg/min for 2 min
Number of subjects: 40
Study 2900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (E) loading dose of 500 micrograms/kg/min for 4 min
Number of subjects: 40
Study 2900819 — intervention group
Group type: COMPARATOR
Intervention: Control group (5% D/W)
Number of subjects: 40
Study 31675174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (radiomics signature + clinical‐radiological risk factors)
Number of subjects: 184